MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours

被引：0
|
作者：
Mikiya Ishihara
Shinichi Kageyama
Yoshihiro Miyahara
Takeshi Ishikawa
Shugo Ueda
Norihito Soga
Hiroaki Naota
Katsumi Mukai
Naozumi Harada
Hiroaki Ikeda
Hiroshi Shiku
机构：
[1] Cancer Center,Department of Immuno
[2] Mie University Hospital,Gene Therapy
[3] Mie University Graduate School of Medicine,Department of Personalized Cancer Immunotherapy
[4] Mie University Graduate School of Medicine,Department of Gastroenterology and Hepatology
[5] Kyoto Prefectural University of Medicine,Department of Gastroenterological Surgery and Oncology
[6] Kitano Hospital,Department of Urology
[7] The Tazuke Kofukai Medical Research Institute,Department of Gastroenterology
[8] Aichi Cancer Center Hospital,Department of Gastroenterology
[9] Matsusaka Chuo General Hospital,Department of Oncology
[10] Suzuka General Hospital,undefined
[11] United Immunity,undefined
[12] Co.,undefined
[13] Ltd,undefined
[14] Nagasaki University Graduate School of Biomedical Sciences,undefined
来源：
BMC Cancer | / 20卷
关键词：
MAGE-A4; NY-ESO-1; qRT-PCR; SAGE; Solid tumour;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Expression of MAGE-A1, MAGE-A3/4 and NY-ESO-1 Cancer-Testis Antigens in Fetal Testis
    Hudolin, Tvrtko
    Kastelan, Zeljko
    Derezic, Danijel
    Basic-Jukic, Nikolina
    Spagnoli, Giulio Cesare
    Juretic, Antonio
    Jezek, Davor
    ACTA DERMATOVENEROLOGICA CROATICA, 2009, 17 (02) : 103 - 107
  • [22] MAGE-A 3/4 and NY-ESO-1 antigens expression in metastatic esophageal squamous cell carcinoma
    Bujas, T.
    Marusic, Z.
    Balja, M. Peric
    Mijic, A.
    Kruslin, B.
    Tomas, D.
    EUROPEAN JOURNAL OF HISTOCHEMISTRY, 2011, 55 (01): : 39 - 43
  • [23] Clinicopathological Assessment of Cancer/Testis Antigens NY-ESO-1 and MAGE-A4 in Highly Aggressive Soft Tissue Sarcomas
    Hashimoto, Kazuhiko
    Nishimura, Shunji
    Ito, Tomohiko
    Akagi, Masao
    DIAGNOSTICS, 2022, 12 (03)
  • [24] MAGE-A and NY-ESO-1 expression in cervical cancer: Prognostic factors and effects of chemotherapy
    Napoletano, Chiara
    Bellati, Filippo
    Tarquini, Elisabetta
    Tomao, Federica
    Taurino, Federica
    Spagnoli, Giulio
    Rughetti, Aurelia
    Muzii, Ludovico
    Nuti, Marianna
    Panici, Pierluigi Benedetti
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2008, 198 (01) : 99.e1 - 99.e7
  • [25] Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NY-ESO-1 in cancerous and benign prostatic tissue
    Hudolin, T
    Juretic, A
    Spagnoli, GC
    Pasini, J
    Bandic, D
    Heberer, M
    Kosicek, M
    Cacic, M
    PROSTATE, 2006, 66 (01): : 13 - 18
  • [26] Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NY-ESO-1 in squamous cell carcinoma of the penis
    Hudolin, Tvrtko
    Juretic, Antonio
    Pasini, Josip
    Tomas, Davor
    Spagnoli, Giulio Cesare
    Heberer, Michael
    Dimanovski, Jordan
    Kruslin, Bozo
    UROLOGY, 2006, 68 (01) : 205 - 207
  • [27] Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma
    Dyrskjot, L.
    Zieger, K.
    Lildal, T. Kissow
    Reinert, T.
    Gruselle, O.
    Coche, T.
    Borre, M.
    Orntoft, T. F.
    BRITISH JOURNAL OF CANCER, 2012, 107 (01) : 116 - 122
  • [28] Immunohistochemical analysis of GAGE, MAGE-A4, MAGE-C1, and NY-ESO-1 cancer/testis antigens in carcinomas of the liver and the biliary tract
    Riener, M.-O.
    Wild, P.
    Soll, C.
    Hellerbrand, C.
    Clavien, P. A.
    Moch, H.
    Jochum, W.
    PATHOLOGY RESEARCH AND PRACTICE, 2007, 203 (05) : 257 - 257
  • [29] Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma
    L Dyrskjøt
    K Zieger
    T Kissow Lildal
    T Reinert
    O Gruselle
    T Coche
    M Borre
    T F Ørntoft
    British Journal of Cancer, 2012, 107 : 116 - 122
  • [30] Expression and immunogenicity of NY-ESO-1 in colorectal cancer
    Li, Ya
    Song, Ruifeng
    Li, Xinqiang
    Xu, Feng
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2017, 13 (06) : 3581 - 3585
12345